This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shimada, T. Articles by Yamashita, T. Search for Related Content PubMed PubMed Citation Articles by Shimada, T. Articles by Yamashita, T.

Mutant FGF-23 Responsible for Autosomal Dominant Hypophosphatemic Rickets Is Resistant to Proteolytic Cleavage and Causes Hypophosphatemia in Vivo

Pharmaceutical Research Labs, KIRIN Brewery Co. Ltd. (T.S., T.M., I.U., T.Y., Y.Y., K.O., T.Y.); Department of Medicine, University of Tokyo School of Medicine (Y.T., T.F.); and Department of Laboratory Medicine, University of Tokyo Hospital (S.F.)

Abstract

FGF-23 is involved in the pathogenesis of two similar hypophosphatemic diseases, autosomal dominant hypophosphatemic rickets/osteomalacia (ADHR) and tumor-induced osteomalacia (TIO). We have shown that the overproduction of FGF-23 by tumors causes TIO. In contrast, ADHR derives from missense mutations in FGF-23 gene. However, it has been unclear how those mutations affect phosphate metabolism. Therefore, we produced mutant as well as wild-type FGF-23 proteins and examined their biological activity. Western blot analysis using site-specific antibodies showed that wild-type FGF-23 secreted into conditioned media was partially cleaved between Arg¹⁷⁹ and Ser¹⁸⁰. In addition, further processing of the cleaved N-terminal portion was observed. In constrast, mutant FGF-23 proteins found in ADHR were resistant to the cleavage. In order to clarify which molecule has the biological activity to induce hypophosphatemia, we separated full-length protein, the N-terminal and C-terminal fragments of wild-type FGF-23. When the activity of each fraction was examined in vivo, only the full-length FGF-23 decreased serum phosphate. Mutant FGF-23 protein that was resistant to the cleavage also retained the activity to induce hypophosphatemia. The extent of hypophosphatemia induced by the single administration of either wild-type or the mutant full-length FGF-23 protein was similar. In addition, implantation of CHO cells expressing the mutant FGF-23 protein caused hypophosphatemia and the decrease of bone mineral content. We conclude that ADHR is caused by hypophosphatemic action of mutant full-length FGF-23 proteins that are resistant to the cleavage between Arg¹⁷⁹ and Ser¹⁸⁰.

This article has been cited by other articles:

				B. M. Reilly, P. D. Hart, S. Mascarell, and H. Chatrath A Question Well Put N. Engl. J. Med., April 2, 2009; 360(14): 1446 - 1451. [Full Text] [PDF]

				M. S. Razzaque FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol, March 1, 2009; 296(3): F470 - F476. [Abstract] [Full Text] [PDF]

				H. J. Garringer, M. Malekpour, F. Esteghamat, S. M. J. Mortazavi, S. I. Davis, E. G. Farrow, X. Yu, D. E. Arking, H. C. Dietz, and K. E. White Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E929 - E937. [Abstract] [Full Text] [PDF]

				Y. Kliger, E. Gofer, A. Wool, A. Toporik, A. Apatoff, and M. Olshansky Predicting proteolytic sites in extracellular proteins: only halfway there Bioinformatics, April 15, 2008; 24(8): 1049 - 1055. [Abstract] [Full Text] [PDF]

				M. Suzuki, Y. Uehara, K. Motomura-Matsuzaka, J. Oki, Y. Koyama, M. Kimura, M. Asada, A. Komi-Kuramochi, S. Oka, and T. Imamura {beta}Klotho Is Required for Fibroblast Growth Factor (FGF) 21 Signaling through FGF Receptor (FGFR) 1c and FGFR3c Mol. Endocrinol., April 1, 2008; 22(4): 1006 - 1014. [Abstract] [Full Text] [PDF]

				S. Liu, W. Tang, J. Zhou, L. Vierthaler, and L. D. Quarles Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1636 - E1644. [Abstract] [Full Text] [PDF]

				F. Perwad, M. Y. H. Zhang, H. S. Tenenhouse, and A. A. Portale Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1{alpha}-hydroxylase expression in vitro Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1577 - F1583. [Abstract] [Full Text] [PDF]

				T. Krajisnik, P. Bjorklund, R. Marsell, O. Ljunggren, G. Akerstrom, K. B Jonsson, G. Westin, and T. E Larsson Fibroblast growth factor-23 regulates parathyroid hormone and 1{alpha}-hydroxylase expression in cultured bovine parathyroid cells J. Endocrinol., October 1, 2007; 195(1): 125 - 131. [Abstract] [Full Text] [PDF]

				M. S Razzaque and B. Lanske The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis J. Endocrinol., July 1, 2007; 194(1): 1 - 10. [Abstract] [Full Text] [PDF]

				R. Goetz, A. Beenken, O. A. Ibrahimi, J. Kalinina, S. K. Olsen, A. V. Eliseenkova, C. Xu, T. A. Neubert, F. Zhang, R. J. Linhardt, et al. Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members Mol. Cell. Biol., May 1, 2007; 27(9): 3417 - 3428. [Abstract] [Full Text] [PDF]

				S. Ichikawa, E. A. Imel, A. H. Sorenson, R. Severe, P. Knudson, G. J. Harris, J. L. Shaker, and M. J. Econs Tumoral Calcinosis Presenting with Eyelid Calcifications due to Novel Missense Mutations in the Glycosyl Transferase Domain of the GALNT3 Gene J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4472 - 4475. [Abstract] [Full Text] [PDF]

				H. J. Garringer, C. Fisher, T. E. Larsson, S. I. Davis, D. L. Koller, M. J. Cullen, M. S. Draman, N. Conlon, A. Jain, N. S. Fedarko, et al. The Role of Mutant UDP-N-Acetyl-{alpha}-D-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase 3 in Regulating Serum Intact Fibroblast Growth Factor 23 and Matrix Extracellular Phosphoglycoprotein in Heritable Tumoral Calcinosis J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4037 - 4042. [Abstract] [Full Text] [PDF]

				G. J. Strewler Disordered Secretion of FGF23 Links Three Disorders of Phosphate Transport IBMS BoneKEy, August 1, 2006; 3(8): 14 - 17. [Full Text] [PDF]

				D. M. Antoniucci, T. Yamashita, and A. A. Portale Dietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3144 - 3149. [Abstract] [Full Text] [PDF]

				K. Kato, C. Jeanneau, M. A. Tarp, A. Benet-Pages, B. Lorenz-Depiereux, E. P. Bennett, U. Mandel, T. M. Strom, and H. Clausen Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis: SECRETION OF FIBROBLAST GROWTH FACTOR 23 REQUIRES O-GLYCOSYLATION J. Biol. Chem., July 7, 2006; 281(27): 18370 - 18377. [Abstract] [Full Text] [PDF]

				E. A. Imel, M. Peacock, P. Pitukcheewanont, H. J. Heller, L. M. Ward, D. Shulman, M. Kassem, P. Rackoff, M. Zimering, A. Dalkin, et al. Sensitivity of Fibroblast Growth Factor 23 Measurements in Tumor-Induced Osteomalacia J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2055 - 2061. [Abstract] [Full Text] [PDF]

				K. E. White, T. E. Larsson, and M. J. Econs The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23 Endocr. Rev., May 1, 2006; 27(3): 221 - 241. [Abstract] [Full Text] [PDF]

				H. Kurosu, Y. Ogawa, M. Miyoshi, M. Yamamoto, A. Nandi, K. P. Rosenblatt, M. G. Baum, S. Schiavi, M.-C. Hu, O. W. Moe, et al. Regulation of Fibroblast Growth Factor-23 Signaling by Klotho J. Biol. Chem., March 10, 2006; 281(10): 6120 - 6123. [Abstract] [Full Text] [PDF]

				A. Syal, S. Schiavi, S. Chakravarty, V. Dwarakanath, R. Quigley, and M. Baum Fibroblast growth factor-23 increases mouse PGE2 production in vivo and in vitro Am J Physiol Renal Physiol, February 1, 2006; 290(2): F450 - F455. [Abstract] [Full Text] [PDF]

				F. Perwad, N. Azam, M. Y. H. Zhang, T. Yamashita, H. S. Tenenhouse, and A. A. Portale Dietary and Serum Phosphorus Regulate Fibroblast Growth Factor 23 Expression and 1,25-Dihydroxyvitamin D Metabolism in Mice Endocrinology, December 1, 2005; 146(12): 5358 - 5364. [Abstract] [Full Text] [PDF]

				T. J. Berndt, S. Schiavi, and R. Kumar "Phosphatonins" and the regulation of phosphorus homeostasis Am J Physiol Renal Physiol, December 1, 2005; 289(6): F1170 - F1182. [Abstract] [Full Text] [PDF]

				O. I. Kolek, E. R. Hines, M. D. Jones, L. K. LeSueur, M. A. Lipko, P. R. Kiela, J. F. Collins, M. R. Haussler, and F. K. Ghishan 1{alpha},25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport Am J Physiol Gastrointest Liver Physiol, December 1, 2005; 289(6): G1036 - G1042. [Abstract] [Full Text] [PDF]

				T. Shimada, Y. Yamazaki, M. Takahashi, H. Hasegawa, I. Urakawa, T. Oshima, K. Ono, M. Kakitani, K. Tomizuka, T. Fujita, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism Am J Physiol Renal Physiol, November 1, 2005; 289(5): F1088 - F1095. [Abstract] [Full Text] [PDF]

				K. Araya, S. Fukumoto, R. Backenroth, Y. Takeuchi, K. Nakayama, N. Ito, N. Yoshii, Y. Yamazaki, T. Yamashita, J. Silver, et al. A Novel Mutation in Fibroblast Growth Factor 23 Gene as a Cause of Tumoral Calcinosis J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5523 - 5527. [Abstract] [Full Text] [PDF]

				S. M. Jan de Beur Tumor-Induced Osteomalacia JAMA, September 14, 2005; 294(10): 1260 - 1267. [Abstract] [Full Text] [PDF]

				T. Larsson, S. I. Davis, H. J. Garringer, S. D. Mooney, M. S. Draman, M. J. Cullen, and K. E. White Fibroblast Growth Factor-23 Mutants Causing Familial Tumoral Calcinosis Are Differentially Processed Endocrinology, September 1, 2005; 146(9): 3883 - 3891. [Abstract] [Full Text] [PDF]

				E. A. Imel and M. J. Econs Fibroblast Growth Factor 23: Roles in Health and Disease J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2565 - 2575. [Full Text] [PDF]

				O. Gutierrez, T. Isakova, E. Rhee, A. Shah, J. Holmes, G. Collerone, H. Juppner, and M. Wolf Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2205 - 2215. [Abstract] [Full Text] [PDF]

				P. J. Tebben, K. R. Kalli, W. A. Cliby, L. C. Hartmann, J. P. Grande, R. J. Singh, and R. Kumar Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors Mayo Clin. Proc., June 1, 2005; 80(6): 745 - 751. [Abstract] [PDF]

				A. Benet-Pages, P. Orlik, T. M. Strom, and B. Lorenz-Depiereux An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia Hum. Mol. Genet., February 1, 2005; 14(3): 385 - 390. [Abstract] [Full Text] [PDF]

				M. Baum, O. W. Moe, J. Zhang, V. Dwarakanath, and R. Quigley Phosphatonin washout in Hyp mice proximal tubules: evidence for posttranscriptional regulation Am J Physiol Renal Physiol, February 1, 2005; 288(2): F363 - F370. [Abstract] [Full Text] [PDF]

				H. Saito, A. Maeda, S.-i. Ohtomo, M. Hirata, K. Kusano, S. Kato, E. Ogata, H. Segawa, K.-i. Miyamoto, and N. Fukushima Circulating FGF-23 Is Regulated by 1{alpha},25-Dihydroxyvitamin D3 and Phosphorus in Vivo J. Biol. Chem., January 28, 2005; 280(4): 2543 - 2549. [Abstract] [Full Text] [PDF]

				G. J. Strewler Phos, Phex and FGF: Mysteries of Phosphate Homeostasis Revealed - or Still Hidden IBMS BoneKEy, September 1, 2004; 1(9): 6 - 14. [Full Text] [PDF]

				P. S.N. Rowe THE WRICKKENED PATHWAYS OF FGF23, MEPE AND PHEX Critical Reviews in Oral Biology & Medicine, September 1, 2004; 15(5): 264 - 281. [Abstract] [Full Text] [PDF]

				R. D. Blank A Thematic Overview of Some Recent Advances in Skeletal Genetics IBMS BoneKEy, July 1, 2004; 1(7): 4 - 12. [Full Text] [PDF]

				C. R. Dunstan, H. Zhou, and M. J. Seibel Fibroblast Growth Factor 23: A Phosphatonin Regulating Phosphate Homeostasis? Endocrinology, July 1, 2004; 145(7): 3084 - 3086. [Full Text] [PDF]

				T. Larsson, R. Marsell, E. Schipani, C. Ohlsson, O. Ljunggren, H. S. Tenenhouse, H. Juppner, and K. B. Jonsson Transgenic Mice Expressing Fibroblast Growth Factor 23 under the Control of the {alpha}1(I) Collagen Promoter Exhibit Growth Retardation, Osteomalacia, and Disturbed Phosphate Homeostasis Endocrinology, July 1, 2004; 145(7): 3087 - 3094. [Abstract] [Full Text] [PDF]

				S. Liu, R. Guo, L. G. Simpson, Z.-S. Xiao, C. E. Burnham, and L. D. Quarles Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX J. Biol. Chem., September 26, 2003; 278(39): 37419 - 37426. [Abstract] [Full Text] [PDF]

				Y. Kida, S. Fukumoto, T. Yamashita, K. Jonsson, M. Econs, and H. Juppner Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia N. Engl. J. Med., July 31, 2003; 349(5): 505 - 506. [Full Text] [PDF]

				L. D. Quarles FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E1 - E9. [Abstract] [Full Text] [PDF]

				R. J. Singh and R. Kumar Fibroblast Growth Factor 23 Concentrations in Humoral Hypercalcemia of Malignancy and Hyperparathyroidism Mayo Clin. Proc., July 1, 2003; 78(7): 826 - 829. [Abstract] [PDF]

				K. B. Jonsson, R. Zahradnik, T. Larsson, K. E. White, T. Sugimoto, Y. Imanishi, T. Yamamoto, G. Hampson, H. Koshiyama, O. Ljunggren, et al. Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia N. Engl. J. Med., April 24, 2003; 348(17): 1656 - 1663. [Abstract] [Full Text] [PDF]

				X.-Y. Bai, D. Miao, D. Goltzman, and A. C. Karaplis The Autosomal Dominant Hypophosphatemic Rickets R176Q Mutation in Fibroblast Growth Factor 23 Resists Proteolytic Cleavage and Enhances in Vivo Biological Potency J. Biol. Chem., March 7, 2003; 278(11): 9843 - 9849. [Abstract] [Full Text] [PDF]

				H. Saito, K. Kusano, M. Kinosaki, H. Ito, M. Hirata, H. Segawa, K.-i. Miyamoto, and N. Fukushima Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1alpha ,25-Dihydroxyvitamin D3 Production J. Biol. Chem., January 17, 2003; 278(4): 2206 - 2211. [Abstract] [Full Text] [PDF]

				H. S. Tenenhouse and H. Murer Disorders of Renal Tubular Phosphate Transport J. Am. Soc. Nephrol., January 1, 2003; 14(1): 240 - 247. [Full Text] [PDF]